Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials

British Journal of Dermatology

Volumn 166, Issue 1, 2012, Pages 179-188

  Reich, K ^a   Burden, A D ^b   Eaton, J N ^c   Hawkins, N S ^c  

^a DERMATOLOGIKUM HAMBURG   (Germany)

^b WESTERN INFIRMARY   (United Kingdom)

^c ICON PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; RETINOID; TOPICAL AGENT; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AGENTS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84655169696     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10583.x     Document Type: Article

References (32)

1. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10: 1-233, i-iv.
2. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-85. (Pubitemid 352009861)
3. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
4. Reich K, Sinclair R, Roberts G, et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin 2008; 24: 1237-54. (Pubitemid 351741556)
5. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-18.
6. Zhang Z, Schmitt J, Wozel G, Kirch W,. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin 2009; 104: 125-36.
7. Eckermann S, Coory M, Willan AR,. Indirect comparison: relative risk fallacies and odds solution. J Clin Epidemiol 2009; 62: 1031-6.
8. Salanti G, Higgins JP, Ades AE, Ioannidis JP,. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
9. Dias S, Welton NJ, Sutton AJ, Ades AE,. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials, 2011. Available at: (last accessed 20 September 2011).
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
11. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15. (Pubitemid 350298146)
12. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66. (Pubitemid 351239154)
13. Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
14. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32. (Pubitemid 37523083)
15. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74. (Pubitemid 41443403)
16. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
17. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22. (Pubitemid 37448924)
18. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12. (Pubitemid 40933433)
19. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35. (Pubitemid 43038667)
20. van de Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-85.
21. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7. (Pubitemid 32539117)
22. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42. (Pubitemid 39278071)
23. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 3.e1-15.
24. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
25. Dubertret L, Sterry W, Bos JD, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006; 155: 170-81. (Pubitemid 43876411)
26. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13. (Pubitemid 37448923)
27. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52 (3 Pt 1): 425-33.
28. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8. (Pubitemid 40144437)
29. Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006; 45: 605-14.
30. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74. (Pubitemid 351671883)
31. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84. (Pubitemid 351671884)
32. European Medicines Agency. Evaluation of Medicines for Human Use: Assessment Report for Stelara (ustekinumab). London: EMA, 2009. Available at: (last accessed 20 September 2011).